PARIS – Passions still run hot, but this year the presentation of preliminary results from the ADVISE II study came off without any bloodied noses during the hot line late breaking clinical trial session at EuroPCR 2013 (Medical Device Daily, May 17, 2012).

PARIS — "Everyone says there are 60 new systems for renal denervation, but where are they?" asked Mano Iyer, a founder of ReCor Medical (Menlo Park, California) saying he only counts five with a CE mark, so where are the other 55? Iyer has a right to feel confident about the growing strength of his company with a CE Mark and a 50-patient post-market study underway in Europe for one of the most novel systems for renal denervation, the newest device-based treatment category.

PARIS – The contrast is especially sharp in the way clinicians speak about renal denervation and the way companies promote this new procedure. In the language of physicians, the idea that a device-based therapy can reduce or replace drug-based treatment for persistent hypertension is only a "notion," an argument or perhaps a hypothesis. To listen to company representatives, it's a done deal.

PARIS — Next year sessions on new devices for transcatheter aortic valve implantation (TAVI) need to move to the main auditorium to accommodate the crowds.There were as many interventional cardiologists standing outside the room as there were sitting inside. The discussions among presenters and panelists provided insights into the state-of-the-art of this relatively new procedure as important as the clinical findings on the new devices.

PARIS — The tight collaboration between industry and medical professionals is most often the subject of derision, scrutiny and sometimes lawsuits. A report of conflicts of interest with companies is the first slide in presentations by any clinician at a conference and are routinely noted in published articles.